Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant widely used in the treatment of several psychiatric conditions. It is best known as the active ingredient originally marketed under the Prozac® brand and works primarily by increasing serotonergic neurotransmission within the central nervous system.
Fluoxetine selectively inhibits the serotonin transporter (SERT), reducing the reuptake of serotonin (5 hydroxytryptamine or 5 HT) into presynaptic nerve cells. This increases the availability of serotonin within the synaptic space and enhances signaling in neurological pathways involved in mood, anxiety, behavior, and emotional regulation.
Fluoxetine has established indications that include major depressive disorder (MDD), obsessive compulsive disorder (OCD), bulimia nervosa, and panic disorder. Its exact approved indications can vary by jurisdiction and formulation.
One notable pharmacological characteristic of fluoxetine is its long elimination half-life. Its active metabolite, norfluoxetine, also remains in the body for an extended period. As a result, changes in dose or discontinuation may take several weeks to be fully reflected in circulating drug concentrations.
This product provides:
- Active Ingredient: Fluoxetine
- Strength: 20mg per tablet
- Quantity: 100 Tablets
- Drug Class: Selective Serotonin Reuptake Inhibitor (SSRI)
- Dosage Form: Oral Tablet
Fluoxetine 20mg tablets are established prescription formulations, and Health Canada recognizes fluoxetine hydrochloride 20mg products as prescription pharmaceuticals.
Common adverse effects associated with fluoxetine can include nausea, headache, insomnia, nervousness, changes in appetite, sweating, fatigue, and sexual dysfunction. As with other SSRIs, therapeutic improvement may develop gradually rather than immediately.
Fluoxetine also carries important serotonergic safety considerations. Combining it with other medications that significantly increase serotonin can increase the risk of serotonin syndrome, while concurrent or closely timed use with monoamine oxidase inhibitors (MAOIs) is contraindicated. Its long half-life is particularly important when switching between fluoxetine and interacting medications.
Antidepressants can also increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults, particularly during the early stages of treatment or after treatment changes. Patients should be appropriately monitored for worsening mood or unusual behavioural changes.
Fluoxetine is a prescription medication and should be used according to the directions of a qualified healthcare professional.
